Micropharma / Progenity

StarFish Contribution

In 2012, MicroPharma began developing diagnostic and therapeutic technology platforms spearheaded by ingestible devices. StarFish Medical helped develop early concepts and intellectual property in support of the world’s first autonomous ingestible capsules.

Progenity acquired the rights to the technology in 2014. StarFish continued development through to First in Human studies for the Smart Capsule Bacterial Detection System (SCBDS), Recoverable Sampling System (RSS), Drug Delivery System (DDS), and Telemetric Localization Capsule (TLC) capsules. Approximately 2000 capsules were manufactured and delivered through to June 2019.

$100M Valuation

In its June 19, 2020 IPO, Progenity was valued at $677.5M. Progenity is now registered under the ticker NASDAQ:PROG.

Progenity ingestible capsule system packaging and diagnostic capsules for sampling applications
Headshot of Mitch Jones, Chief Scientific Officer and co-founder of MicroPharma

Mitch Jones MD, PHD
Chief Scientific Officer, Co-Founder of Micropharma, VP – Translational and Clinical Development of Progenity, Inc.

Headshot of Ryan Jones, co-founder of MicroPharma and VP at Progenity

Ryan Jones
Co-Founder at Micropharma, VP – Corporate and Business Development at Progenity, Inc.

Technicians assembling ingestible capsules inside the StarFish Medical clean room

Assembling capsules in StarFish clean room.

Interior electronics of Progenity ingestible capsule showing circuitry and components

Interior electronics of capsule.